Advertisement
-
-
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain
De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.
-
-
Trending - Altmetric
-
Long-term outcomes following CAR T cell therapy: what we know so far
-
Current understanding and management of CAR T cell-associated toxicities
-
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
-
Cancer mRNA vaccines: clinical advances and future opportunities